PRURITUS Symptoms and Causes

What is itching?

Itching is an irritating sensation that makes you want to scratch your skin. Sometimes it can feel like pain, but it is different. Often, you feel itchy in one area in your body, but sometimes you may feel itching all over. Along with the itching, you may also have a rash or hives.

What causes itching?

Itching is a symptom of many health conditions. Some common causes are

  • Allergic reactions to food, insect bites, pollen, and medicines
  • Skin conditions such as eczema, psoriasis, and dry skin
  • Irritating chemicals, cosmetics, and other substances
  • Parasites such as pinworms, scabies, head and body lice
  • Pregnancy
  • Liver, kidney, or thyroid diseases
  • Certain cancers or cancer treatments
  • Diseases that can affect the nervous system, such as diabetes and shingles
What are the treatments for itching?

Most itching is not serious. To feel better, you could try

  • Applying cold compresses
  • Using moisturizing lotions
  • Taking lukewarm or oatmeal baths
  • Using over-the-counter hydrocortisone cream or antihistamines
  • Avoiding scratching, wearing irritating fabrics, and exposure to high heat and humidity

Contact your health care provider if your itching is severe, does not go away after a few weeks, or does not have an apparent cause. You may need other treatments, such as medicines or light therapy. If you have an underlying disease that is causing the itching, treating that disease may help.

Check out the latest treatments for PRURITUS

PRURITUS treatment research studies

RIBASPHERE clinical trials, surveys and public health registries

Find Drug Side Effect reports


Fatigue (131)
Anaemia (129)
Depression (100)
Asthenia (95)
Dyspnoea (84)
Nausea (82)
Dizziness (67)
White Blood Cell Count Decreased (63)
Dehydration (62)
Headache (58)
Diarrhoea (53)
Vomiting (52)
Weight Decreased (51)
Anxiety (49)
Alopecia (49)
Insomnia (46)
Condition Aggravated (43)
Platelet Count Decreased (35)
Anger (34)
Chest Pain (34)
Arthralgia (34)
Haemoglobin Decreased (33)
Decreased Appetite (33)
Influenza Like Illness (31)
Pneumonia (30)
Red Blood Cell Count Decreased (29)
Pain (29)
Loss Of Consciousness (29)
Back Pain (28)
Anorexia (27)
Chills (26)
Rash (25)
Fall (25)
Blood Glucose Increased (25)
Crying (25)
Cough (24)
Suicidal Ideation (22)
Pyrexia (21)
Abdominal Pain (21)
Hypertension (21)
Feeling Abnormal (20)
Abdominal Pain Upper (19)
Disturbance In Attention (19)
Blood Potassium Decreased (19)
Irritability (17)
Pregnancy (16)
Confusional State (16)
Paranoia (16)
Myalgia (15)
Pruritus (15)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

PRURITUS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Pregabalin for the Treatment of Uremic Pruritus
Condition: Uremic Pruritus
Interventions: Drug: pregabalin 75mg daily for 12 weeks;   Drug: fexofenadine 60 mg daily for 12 weeks;   Drug: placebo
Outcome Measures: The changes in Pruritus symptoms assessed by VAS;   The changes in Pruritus score (PS), Skindex-10", "Brief Itching Inventory" and Itch Medical Outcomes Study
2 Not yet recruiting Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Conditions: Uremic Pruritus;   Pruritus
Interventions: Drug: nalbuphine HCl ER tablets 60 mg BID;   Drug: nalbuphine HCl ER tablets 120mg BID;   Drug: Placebo tablets BID
Outcome Measures: Change from Baseline to the Evaluation Period (weeks 7 and 8) in itch on the 0-10 Itch Numerical Rating Scale;   Change from Baseline scores to the Evaluation Period (weeks 7 and 8) in the total Skindex-10 score
3 Not yet recruiting Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study
Condition: Pruritus
Interventions: Procedure: Biopsy;   Procedure: Blood
Outcome Measures: the percentage change in pSTAT3 expression among patients reporting a relief in their Pruritus, irrespective of lesion clearing;   IL-31 amount and intensity of cathepsin S expression;   percentage of vasodilatory peptidergic nerves at the dermoepidermal junction as a percentage of total nerves
4 Recruiting Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
Condition: Treatment-resistant Pruritus Associated With Atopic Dermatitis
Interventions: Drug: VLY-686;   Drug: Placebo
Outcome Measures: Efficacy of VLY-686 on reducing chronic Pruritus using Verbal Rating Scale (VRS) score and item 'Pruritus' of Patient Global Assessment (PGA) Likert scale;   Efficacy of VLY-686 on reducing chronic Pruritus using Visual Analog Scale (VAS);   Efficacy of VLY-686 on reducing atopic dermatitis skin lesions using SCORAD;   Evaluate time course changes in VRS scores;   Effect of VLY-686 on physiology of skin as measured by TransEpidermal Water Loss (TEWL);   Effect of VLY-686 on the subjective measure of Patient Benefit Index (PBI).;   Measurement of nerve fiber density and NK-1 receptor density in exploratory skin biopsies.;   Number of adverse events in subjects taking placebo;   Explore the contribution of genetic factors on safety outcomes (e.g. number of adverse events, changes in vital signs, changes in laboratory values).;   Evaluate time course changes in VAS scores;   Explore the contribution of genetic factors on efficacy outcomes (e.g. VRS, VAS, SCORAD);   Number of adverse events in subjects taking VLY-686;   Effect of VLY-686 on physiology of skin as measured by Skin Hydration.;   Efficacy of VLY-686 on reducing atopic dermatitis skin lesions using Eczema Area and Severity Index (EASI);   Effect of VLY-686 on the subjective measure of Dermatology Life Quality Index (DLQI).;   Effect of VLY-686 on the Clinical Global Impression-Change (CGI-C).
5 Unknown  A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)
Condition: Uremic Pruritus
Interventions: Drug: Nalfurafine HCl 2.5 µg;   Drug: Nalfurafine HCl 5.0 µg;   Other: Placebo
Outcome Measure: Primary efficacy endpoint is the change in worst itching intensity from baseline, compared to that in the last two weeks of the double blind, placebo controlled, randomized withdrawal period.
6 Recruiting Naloxone for the Treatment of Opioid-Induced Pruritus
Condition: Pruritus
Interventions: Drug: Naloxone;   Drug: Saline/Morphine
Outcome Measures: Pruritus incidence and intensity;   Self-report pain scores;   Morphine, ondansetron, diphenhydramine utilization
7 Unknown  Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus
Condition: Uremic Pruritus
Interventions: Drug: Pregabalin;   Drug: Placebo
Outcome Measures: Reduction of UP by more than 50% after Pregabalin administration;   Reduction of chronic pain of various origin and improvement in insomnia after Pregabalin administration
8 Recruiting Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
Conditions: Sezary Syndrome;   Pruritus
Interventions: Drug: Aprepitant;   Drug: Placebo
Outcome Measures: Severity of Pruritus;   Quality of life
9 Not yet recruiting Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
Conditions: Uremic Pruritus;   Pruritus
Interventions: Drug: nalbuphine HCl ER 60mg BID;   Drug: nalbuphine HCl ER 90mg BID;   Drug: nalbuphine HCl ER 120mg BID
Outcome Measures: A description of the overall incidence frequency and nature of Treatment Emergent Adverse Events (TEAEs);   A description of the incidence frequency and nature of Treatment Emergent Adverse Events (TEAEs) during Treatment by achieved dose
10 Recruiting Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and Palonosetron
Condition: Morphine Adverse Reaction
Interventions: Drug: Ondansetron;   Drug: Palonosetron
Outcome Measure: Incidence of Pruritus
11 Unknown  Gabapentin - A Solution to Uremic Pruritus?
Conditions: Pruritus;   Uremia
Intervention: Drug: Gabapentin
Outcome Measures: Subjective measurement of reduction in Pruritus;   Tolerability of Gabapentin in CAPD patients
12 Not yet recruiting Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
Condition: Alagille Syndrome
Interventions: Drug: LUM001;   Drug: Placebo
Outcome Measure: Efficacy
13 Recruiting A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus
Condition: Cholestasis, Intrahepatic
Interventions: Drug: GSK2330672;   Drug: Placebo;   Drug: Ursodeoxycholic acid
Outcome Measures: Safety and tolerability assessment following repeat doses of GSK2330672;   Tolerability assessment using Gastrointestinal Symptom Rating Scale (GSRS).;   Fecal occult blood testing;   Steady-state PK assessment of UDCA and its taurine and glycine conjugates taurodeoxycholic acid (TUDCA) and glycoursodeoxcholic acid (GUDCA);   Plasma GSK2330672 PK assessment;   Measurement of serum profiles of total bile acid concentrations and 7-alpha hydroxy-4-cholesten-3-one (C4);   Subject reported outcomes - daily Pruritus 0 to 10 pt scale.;   Subject reported outcomes - 5D-itch scale;   Patient reported outcomes PBC-40 quality of life (QoL) scale.
14 Unknown  Treatment of Uremic Pruritus by Olive-omega 3 Ointment
Condition: Uremic Pruritus
Intervention: Procedure: application of ointment (olive-omega 3 ointment)
Outcome Measure:
15 Not yet recruiting Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching
Condition: Pruritus
Interventions: Drug: Cetirizine;   Drug: Placebo or sugar pill
Outcome Measure: Itch score
16 Recruiting VPD-737 for Treatment of Chronic Pruritus
Condition: Chronic Pruritus
Interventions: Drug: VPD-737;   Drug: Placebo
Outcome Measures: Visual Analog Scale;   Verbal Response Scale
17 Recruiting Hypnosis for Pain and Itch Following Burn Injuries
Condition: Burns
Interventions: Behavioral: Hypnosis;   Other: Standard of Care
Outcome Measures: Change in Numerical Rating Scale for Average Itch;   Change in Numerical Rating Scale for Pain;   Change in Medical Outcomes Study of Sleep;   Change in Leeds Assessment of Neuropathic Symptoms and Signs-Self report;   Change in 5-D Itch Scale;   Change in Post-Traumatic Stress Disorder Checklist-Civilian version
18 Recruiting A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis
Condition: Atopic Dermatitis
Interventions: Drug: CT327 ointment;   Drug: placebo
Outcome Measures: • To determine whether CT327 is effective in reducing Pruritus in subjects with atopic dermatitis, using a Pruritus visual analogue scale (VAS);   • To assess efficacy of CT327 on atopic dermatitis using the Investigator Global Assessment (IGA)
19 Recruiting Pruritus in Patients With Chronic Kidney Disease
Conditions: Kidney Failure, Chronic;   Pruritus
Intervention: Other: Questionnaire based on the McGill Pain Questionnaire
Outcome Measure:
20 Unknown  Efficacy Study of Two Choices of Phototherapy on Itching Skin Diseases
Conditions: Eczema;   Psoriasis
Interventions: Device: UVA / UVB phototherapy;   Device: UVB phototherapy
Outcome Measure: 5-D Pruritus score and VAS Score at 16 weeks